News | November 09, 2006

Medtronic Pursues Minimally Invasive AF Treatment

Medtronic, Inc. has the FDA’s approval to initiate the Feasibility of the Lone Atrial Fibrillation Clinical Trial (FACT), which coincides with the launch of Medtronic’s Cardioblate Navigator Tissue Dissector.

The purpose of the FACT feasibility clinical trial is to evaluate the use of the Cardioblate Surgical Ablation System thorascopically in paroxysmal atrial fibrillation patients. The prospective, non-randomized, feasibility clinical trial will enroll 15 patients at three U.S. medical centers including Scott & White Memorial Hospital (Temple, TX), Beth Israel Hospital (Boston, MA), and LDS Hospital (Salt Lake City, UT). The primary endpoints of the trial are to evaluate the freedom of symptomatic paroxysmal AF episodes using Cardioblate surgical ablation devices in lone AF patients.

While none of the devices used in the trial are investigational, results of the trial will be used to design U.S. pivotal studies for an additional indication of use for the Cardioblate Surgical Ablation System in the U.S. to treat paroxysmal atrial fibrillation. The commercial release of the Navigator Tissue Dissector complements Medtronic’s Cardioblate family of bipolar solutions with technology for this stand-alone, surgical ablation procedure.

For further information visit

Related Content

Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biosense webster multielectrode balloon RF ablation catheter

The Biosense Webster multi-electrode balloon RF ablation catheter. Each electrode can have varied power settings to avoid damage to underlying tissues like the esophagus. 

Feature | EP Lab| June 22, 2017 | Dave Fornell
Electrophysiology (EP) technology has been advancing rapidly the past few years with new ablation tools to improve...
Sponsored Content | Videos | EP Lab| May 26, 2017
DAIC Editor Dave Fornell takes a tour of some of the most innovative new electrophysiology (EP) technology at the 201
Sponsored Content | Videos | Atrial Fibrillation| May 17, 2017
Hugh Calkins, M.D., FACC, FAHA, FHRS, director of cardiac arrhythmia services and professor of medicine at Johns Hopk
Biosense Webster multi-electrode RF ablation balloon

Biosense Webster's multi-electrode RF ablation balloon with irrigation. The system allows operators to change the energy levels of each electrode to avoid damaging sensitive underlying critical structures like the esophagus or phrenic nerve.

Feature | Ablation Systems| May 17, 2017 | Dave Fornell
May 17, 2017 – Clinical trial results from a first-in-human study evaluating the acute feasibility of an investigatio
Abbott Announces CE Mark for New Cardiac Ablation Catheter
News | Ablation Systems| May 10, 2017
Abbott announced CE Mark of the TactiCath Contact Force Ablation Catheter, Sensor Enabled, developed to make it easier...
The Arctic Front Advance Cardiac CryoAblation Catheter treats atrial fibrillation with pulmonary vein isolation
News | Atrial Fibrillation| April 11, 2017
April 10, 2017 — Medtronic recently announced the first enrollments in the STOP Persistent AF clinical trial.
Overlay Init